Cargando…
Does the development of new medicinal products in the European Union address global and regional health concerns?
BACKGROUND: Since 1995, approval for many new medicinal products has been obtained through a centralized procedure in the European Union. In recent years, the use of summary measures of population health has become widespread. We investigated whether efforts to develop innovative medicines are focus...
Autores principales: | Catalá-López,, Ferrán, García-Altés,, Anna, Álvarez-Martín, Elena, Gènova-Maleras, Ricard, Morant-Ginestar, Consuelo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017015/ https://www.ncbi.nlm.nih.gov/pubmed/21172012 http://dx.doi.org/10.1186/1478-7954-8-34 |
Ejemplares similares
-
Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?
por: Catalá-López, Ferrán, et al.
Publicado: (2011) -
The burden of premature mortality in Spain using standard expected years of life lost: a population-based study
por: Gènova-Maleras, Ricard, et al.
Publicado: (2011) -
Burden of disease due to cancer in Spain
por: Fernández de Larrea-Baz, Nerea, et al.
Publicado: (2009) -
Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies
por: Catalá-López, Ferrán, et al.
Publicado: (2012) -
Prevalence and comorbidity of attention deficit hyperactivity disorder in Spain: study protocol for extending a systematic review with updated meta-analysis of observational studies
por: Catalá-López, Ferrán, et al.
Publicado: (2019)